Form 4 for RVMD Revolution Medicines, Inc.
Accepted 2022-06-10 00:00:00 ET · period of report 2022-06-08 · accession 0000899243-22-022011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-06-10 | 2022-06-08 | RVMD | Exter Neil | Dir | S - Sale | — | 0 | 0 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-08 | S | D | 0 | $0.00 | 0 | I See footnote | — | — | (F1) On June 8, 2022, Third Rock Ventures III, L.P. ("TRV III") sold 419,901 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $20.25 to $20.41, inclusive, at a weighted average price per share of $20.25. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). (F2) After the above transaction, TRV III owned 5,104,130 shares of Common Stock of the Issuer. (F3) The Reporting Person is a partner of each of TRV GP III, L.P. and Third Rock Ventures GP IV, L.P. which is the general partner of each of TRV III and Third Rock Ventures IV, L.P. ("TRV IV" and collectively with TRV III, "the Funds"), respectively. The Reporting Person disclaims beneficial ownership over the shares held by the Funds, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. |